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Abstract
Background: Autoantibodies to GAD65 (anti-GAD65) are present in the sera of 70–80% of patients with type 1 diabetes
(T1D), but antibodies to the structurally similar 67 kDa isoform GAD67 are rare. Antibodies to GAD67 may represent a cross-
reactive population of anti-GAD65, but this has not been formally tested.
Methodology/Principal Findings: In this study we examined the frequency, levels and affinity of anti-GAD67 in diabetes sera
that contained anti-GAD65, and compared the specificity of GAD65 and GAD67 reactivity. Anti-GAD65 and anti-GAD67 were
measured by radioimmunoprecipitation (RIP) using
125I labeled recombinant GAD65 and GAD67. For each antibody
population, the specificity of the binding was measured by incubation with 100-fold excess of unlabeled GAD in homologous
and heterologous inhibition assays, and the affinity of binding with GAD65 and GAD67 was measured in selected sera. Sera
werealsotestedforreactivitytoGAD65andGAD67byimmunoblotting.Ofthe85serathatcontainedantibodiestoGAD65,28
contained anti–GAD67 measured by RIP. Inhibition with unlabeled GAD65 substantially or completely reduced antibody
reactivity with both
125I GAD65 and with
125I GAD67. In contrast, unlabeled GAD67 reduced autoantibody reactivity with
125I
GAD67 but not with
125I GAD65. Both populations of antibodies were of high affinity (.10
10 l/mol).
Conclusions: Our findings show that autoantibodies to GAD67 represent a minor population of anti-GAD65 that are reactive
with a cross-reactive epitope found also on GAD67. Experimental results confirm that GAD65 is the major autoantigen in
T1D, and that GAD67 per se has very low immunogenicity. We discuss our findings in light of the known similarities between
the structures of the GAD isoforms, in particular the location of a minor cross-reactive epitope that could be induced by
epitope spreading.
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Introduction
Glutamic acid decarboxylase 65 (GAD65), a neuroendocrine
enzyme, is a key autoantigen in type 1 diabetes (T1D) [1], in
Latent Autoimmune Diabetes of Adults (LADA) [2] and in various
neurological diseases [3,4,5,6,7]. Serum autoantibodies to GAD65
are an important marker in the early prediction and diagnosis of
T1D [8,9]. The closely related 67 kDa isoform, GAD67, is 71%
identical in its amino acid sequence but is rarely an autoantigen in
T1D [1,10,11], interacts differently with the pyridoxal-59-phosphate
(PLP) co-factor, and has different kinetics for GABA synthesis in
enzyme activity assays [12].
Recently, the crystal structures of human GAD65 and GAD67
were determined [13], and provided a unique insight into the
structural basis for autoantigenicity of these closely related
isoforms [13,14,15]. Analysis of the structures of the protein
isoforms has allowed the identification of independent B-cell
epitope clusters that locate on opposing faces of the C-terminal
domains on GAD65 but not on GAD67 [14]. Structural
comparisons revealed two key differences between the isoforms.
First, GAD65 is more flexible than GAD67, mainly at the C-
terminal domains and at the catalytic loop residues. Second, there
are striking differences between these isoforms in their electrostatic
charge distribution [15,16]. These structural and physicochemical
differences correlate with known epitope regions in the antigenic
isoform GAD65, revealing how the immunodominant epitopes on
GAD65 are highly mobile and charged, relative to the
corresponding regions in the non-antigenic isoform GAD67
[11,15,16]. Although anti-GAD67 antibodies are rare, these
antibodies may represent a cross-reactive population of anti-
GAD65 [17,18], but this has not been formally tested. We
wondered whether this cross-reactivity might reveal insights into
the structural similarities between the isoforms. We therefore set
out to more closely examine the reactivity of anti-GAD65 and
anti-GAD67 in sera selected to contain anti-GAD65.
Methods
Ethics statement
Human sera were originally obtained with written consent, and
were derived from previous clinical and epidemiological studies on
antibodies to GAD65 approved by the Monash University Human
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18411Research Ethics Committee (MUHREC). The sera had been
stored without identifying information as a source of control sera
to validate new anti-GAD assays, and their use for the present
study was approved by MUHREC.
Sera
Eighty five stored sera that contained anti-GAD65 were selected
for study. Selection was based on the availability of sufficient
serum for repeat assays and the known presence of anti-GAD65 in
the serum. There was a bias towards sera containing high levels of
anti-GAD65, considered more likely to contain anti-GAD67, but
levels of anti-GAD65 ranged from 30 to .10,000 World Health
Organization (WHO) units [19,20]. Clinical details were limited,
but the patients were adults, with T1D or Latent Autoimmune
Diabetes of Adults, (LADA) of varying duration. The mouse
monoclonal antibody GAD6 [21,22] was used as a positive
control. Ten sera known not to contain anti-GAD65 (2–11 WHO
units) from healthy laboratory personnel were also tested, and
pooled normal serum from five blood donors was included as a
negative control in each assay.
Radioimmunoprecipitation assay (RIP)
Recombinant human GAD65 and GAD67 (rGAD65, rGAD67)
expressed in Saccharomyces cerevisiae [23,24] were used for all
experiments. Both proteins were N-terminally truncated, and
contained a hexahistidine tag at the C-terminal end to facilitate
purification. However both constructs retained full enzyme activity
[13], and the GAD65 construct retained all of the reactivity with
diabetes sera of full length rGAD65 [23,24]. Each antigen was
iodinated using chloramine T, and anti-GAD levels were
measured using a standard radioimmunoprecipitation assay
(RIP) previously used in antibody standardization workshops
[19,20]. In brief, 10 ml of serum and 50 mlo f
125I GAD containing
50,000 cpm were incubated overnight at 4uC. Antigen-antibody
complexes were precipitated by the addition of 50 ml of a 50%
slurry of Protein A Sepharose (4B conjugate, ZYMED, South San
Francisco CA, USA), pelleted by centrifugation, and the
percentage of radioactivity in the pellet was calculated.
The specificity of binding of anti-GAD was measured for
selected sera by competitive binding experiments in which a 100-
fold excess of unlabeled GAD65 or GAD67 (8610
29 M) was
added to the standard RIP containing
125I labeled GAD65 or
GAD67. Homologous cross inhibition was performed using
125I
GAD65 with unlabeled GAD65 and
125I GAD67 with unlabeled
GAD67. Heterologous cross inhibition was performed using
125I
GAD65 with unlabeled GAD67 and
125I GAD67 with unlabeled
GAD65. All assays were performed in duplicate.
Anti-GAD affinity measurements
The affinity of anti-GAD67 and/or anti-GAD65 in selected sera
was measured by competitive binding experiments based on those
described by Mayr et al [25]. For each antigen, the serum was
titrated using 10-fold dilutions in the RIP to select a serum dilution
at the top of the linear range of the titration curve for use in the
affinity assay. This serum dilution was then tested by RIP in which
serum was incubated with
125I GAD65 or
125I GAD67 in the
presence of five 10-fold dilutions of unlabeled GAD65
(1.6610
211 M–1.6610
27 M) or GAD67 (1.7610
211 M–
1.7610
27 M) or assay buffer only. Following incubation, the
assay was completed as for the standard RIP. IC50 and Kd values
were calculated by nonlinear regression analysis using GraphPad
Prism5 software (GraphPad Software, San Diego, California).
Displacement curves were plotted using counts per minutes for
each competition reaction on the Y-axis and the logarithmic
concentration of unlabeled GAD on the X-axis. The anti-GAD
affinity value was expressed as the reciprocal of Kd (l/mol).
Measurement of anti-GAD65 and anti-GAD67 by
immunoblotting
Recombinant GAD65 and GAD67 separated by 10% SDS
PAGE were transferred by electrophoresis to polyvinylidene
difluoride (PVDF) membrane, blocked with 4.5% skimmed milk
in Tris buffered saline pH 7.5 containing 0.1% Tween 20 (TBST)
for one hour and washed three times with TBST. The membrane
was incubated with serum diluted 1: 500 or 1:1000 fold in TBST,
for 1 hour at room temperature, washed, and incubated with
horseradish peroxidase conjugated goat anti-human IgG (Milli-
pore, Melbourne, Australia) or sheep anti-mouse IgG (Millipore),
diluted 500 or 1000 fold in TBST. The mouse mAb GAD6,
reactive with GAD65, and a normal human serum were included
in each test as positive and negative controls. The protein bands
were viewed by Amersham Enhanced Chemiluminescence
Blotting Detection Reagent (GE Healthcare, Buckingham-shire,
UK) with exposure on a Fujifilm Luminescent Image Analyser for
one minute.
Results
Antibodies to GAD65 and GAD67 detected by RIP
The levels of anti-GAD67 and anti-GAD65 in sera from 85
patients are shown in Figure 1a. For direct comparison the levels
of antibodies were expressed as the percent of the total counts of
radioactivity (%TC) precipitated by each serum, as the two
isoforms contain the same number of tyrosine residues, and the
final
125I-GAD65 and
125I-GAD67 preparations had similar
specific activity. The cut-off for positivity for each assay was
defined as %TC greater than the mean+3 standard deviations for
the 10 healthy controls, which was 1.3 for anti-GAD65, and 5 for
anti-GAD67. Using these cut-offs, all 85 sera from patients
contained anti-GAD65, and 28 (33%) contained anti-GAD67. For
anti-GAD65, there was a close linear relationship between %TC
precipitated and WHO units up to ,20–25%TC (data not
shown), which represented approximately 100 WHO units of anti-
GAD65, but beyond this the amount of reactivity precipitated
began to plateau, and titration was required for quantitative
analysis. For many sera that contained the highest levels of anti-
GAD65, the %TC precipitated by serum diluted 1:10 or 1:100
was equal to or greater than the %TC precipitated by undiluted
serum (Figure 1b).
Although there was little correlation between the levels of anti-
GAD65 and anti-GAD67 in sera (Figure 1a, R
2=0.321), anti-
GAD67 were more common in sera that contained high levels of
anti-GAD65, being detected in 25 of 43 (58%) sera with levels of
anti-GAD65 .20%TC, but in only 2 of 42 (5%) sera that
contained anti-GAD65 ,20%TC (P,0.0001). Also, titration
indicated that for many sera, the amount of anti-GAD65 was
10–100-fold higher than anti-GAD67 in the same serum
(Figure 1b).
Antibodies to GAD65 and GAD67 by immunoblotting
None of the sera tested for reactivity with GAD65 and GAD67
by immunoblotting reacted strongly with either antigen. Of 23
sera tested, 10 were weakly positive on at least one occasion with
GAD65, and 13 were weakly positive with GAD67, but the results
showed poor reproducibility. In contrast, the mouse mAb GAD6
that was used as a positive control reacted strongly and consistently
with GAD65.
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The affinity of anti-GAD65 and anti-GAD67 in five sera that
contained both anti-GAD65 and anti-GAD67 was compared with
the affinity of anti-GAD65 in five sera that contained only anti-
GAD65 (Table 1). All sera contained high affinity antibodies,
ranging from 9610
9–9.4610
10 l/moles for anti-GAD65, and the
dual-reactive sera had an affinity range of 4.8610
9–1.5610
10 l/
moles for anti-GAD67. Although levels of anti-GAD67 were much
lower than levels of anti-GAD65 in the sera tested, there were no
large differences in the affinity of the two populations, and the
affinity was not related to the level of the antibodies present, as
judged by the serum dilution at which the affinity was measured
(Table 1).
Specificity of antibodies to GAD67
To determine whether the populations of anti-GAD67 and anti-
GAD65 were cross-reactive, 30 sera were tested in heterologous
competition assays in which the binding of the radiolabeled GAD65
or GAD67 was inhibited with unlabeled heterologous GAD, and 17
sera were tested both by homologous and heterologous inhibition.
Results for three representative sera are shown in Figure 2a,b, and
mean results forall sera testedareshowninTable2.Byhomologous
inhibition, anti-GAD65 was inhibited by unlabeled GAD65, and
anti-GAD67 was inhibited by unlabeled GAD67, as expected
(Figure 2a,b). In contrast, by heterologous inhibition, anti-GAD67
in most sera was strongly and significantly (P,0.0001) inhibited by
unlabeled GAD65, whereas anti-GAD65 was not inhibited by
unlabeled GAD67; in almost all cases, inhibition was complete
(,2%TC residual activity) except in sera that contained very high
levels of antibody (.30%TC) to GAD67. Taken together these
results suggested that anti-GAD67 reactivity usually represents a
small population of the total anti-GAD65 that react with an epitope
shared between the two isoforms. However, there were two
exceptional sera. In the first serum that contained both anti-
GAD65 (35%TC) and anti-GAD67 (20%TC), anti-GAD67 was
completely inhibited by unlabeled GAD65, but unlabeled GAD67
also substantially inhibited anti-GAD65, reducing the reactivity to
9%TC, suggesting that anti-GAD reactive with an epitope present
on both GAD65 and GAD67 was a major component of the
autoantibody population. For the second serum (anti-GAD65
9%TC; anti-GAD67 17%TC), GAD65 did not inhibit anti-
GAD67, although competition with each of the homologous
antigens caused complete inhibition, indicating that the two
antibody populations were not cross-reactive.
Discussion
In this study we have shown that anti-GAD67 occur in a
minority of patients with T1D or LADA who have anti-GAD65.
The autoantibodies were readily detected by RIP, but not by
immunoblotting indicating that, like anti-GAD65, they reacted
with conformational epitopes. Overall anti-GAD67 were rarely
detected in sera that did not contain high levels of anti-GAD65,
and levels of anti-GAD67 were generally 1–10% of the level of
anti-GAD65 in the same serum, but the affinity of binding was
similarly high for each population of antibodies. As expected, anti-
GAD67 reactivity was readily inhibited by the addition of
unlabelled GAD67, but unexpectedly, it was also strongly
inhibited by the addition of unlabelled GAD65, whereas anti-
GAD65 reactivity was inhibited only with GAD65. Taken
together, these results indicate that for most sera anti-GAD67
represents a minor population of anti-GAD65 reactive with an
epitope shared between GAD65 and GAD67.
The location of such a cross-reactive epitope is unknown, but
several lines of evidence suggest that it is not in the C-terminal
domain(s) of GAD65 that have previously been identified as the
likely location for major epitopes for anti-GAD65 in diabetes [14].
First, as part of previous epitope mapping studies [26] a mutant
was identified in which the amino acids 572DF573 in the C-terminal
domain were replaced by alanines. This mutation was thought to
cause a major conformational change, particularly in the C-
terminus which destroyed the reactivity to GAD65 of the human
Figure 1. Antibodies to GAD65 and GAD67 detected by RIP. (a) Comparison of antibody reactivity to GAD65 (x-axis) and to GAD67 (y-axis),
measured as the percent of the total counts of radioactivity precipitated by each serum (%Total counts) in 85 sera that contain anti-GAD65. The
horizontal dotted line indicates the upper limit of normal for anti-GAD67 and the vertical dotted line indicates the upper limit of normal for anti-
GAD65, based on mean+3SD of reactivity of 10 normal controls. None of the normal controls showed any reactivity beyond these levels. (b) Titration
curves for anti-GAD65 and anti-GAD67 in three representative sera that contain high levels of both anti-GAD65 and anti-GAD67. ,( %) and (m)
represent three different sera samples.
doi:10.1371/journal.pone.0018411.g001
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most diabetes sera tested. Interestingly, the diabetes sera in which
anti-GAD65 reactivity was not completely removed were sera that
contained both anti-GAD65 and anti-GAD67 [26], (and unpub-
lished observations). Further evidence for the lack of a conforma-
tional epitope in the C-terminal domain of GAD67 has come from
structural studies of a GAD67 mutant that contains the GAD65-
catalytic loop (amino acids 423–433). This mutation results in
structural changes in the C-terminal domain, but no alteration in
anti-GAD67 reactivity (G. Fenalti, personal communication).
The clinical significance of anti-GAD67 in T1D remains
unclear. In the present study, sera were selected to contain high
levels of anti-GAD65, and according to the availability of sufficient
serum, and were not suitable for an unbiased clinical evaluation.
However the study does raise the question of the clinical
significance of these antibodies. It is important to note that sera
from patients with some neurological diseases, particularly stiff
person syndrome (SPS), contain high levels of both anti-GAD65
and anti-GAD67 [6,7], and the anti-GAD reactivity in these
patients may differ from that in T1D. Sera from patients with SPS
Table 1. Affinity of anti-GAD65 and anti-GAD67 in five sera that contain both anti-GAD65 and anti-GAD67 and in five that contain
anti-GAD65 only.
Serum Anti-GAD65 Anti-GAD67
Antibody
(%TC) Dilution tested
Affinity
(l/mol)
Antibody
(%TC) Dilution tested
Affinity
(l/mol)
1 29.8 1 : 500 1610
10 42.6 1 : 100 1610
10
2 16.6 1 : 100 9610
9 11.9 1 : 10 8610
9
3 27.8 1 : 100 1610
10 21.6 undiluted 4.8610
10
4 14.5 1 : 5 6.7610
10 15.5 undiluted 1.5610
10
5 20.5 1 : 100 9.4610
10 27.8 undiluted 1.3610
10
6 18.1 1 : 10 1.4610
10 2.6 - - - -
7 12.8 undiluted 2.7610
10 0.6 - - - -
8 7.2 undiluted 1.2610
10 0.6 - - - -
9 5.6 1 : 5 2.2610
10 1.6 - - - -
10 5.5 1 : 10 12.1610
10 1.1 - - - -
doi:10.1371/journal.pone.0018411.t001
Figure 2. Competition assays to measure cross-reactivity of anti-GAD65 (a) and anti-GAD67 (b). Results, shown as mean and range of
duplicates, of inhibition assay for three representative sera inhibited with GAD65 and GAD67. Reactivity with
125I-GAD65 or
125I-GAD67 (dark grey
bars) was inhibited with 100-fold excess of the same GAD (homologous inhibition, black bars). In contrast, unlabelled GAD65 substantially or
completely inhibited anti-GAD67, although unlabelled GAD67 did not inhibit anti-GAD65 reactivity (heterologous inhibition, light grey bars).
doi:10.1371/journal.pone.0018411.g002
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inhibit GAD enzyme activity [27,28], and interestingly, anti-GAD
reactivity by immunoblotting in SPS-sera is with GAD65 but not
GAD67 [28]. Anti-GAD, including both anti-GAD65 and anti-
GAD67 can be detected by immunofluorescence on brain in SPS
but not in T1D [29], and this anti-GAD67 detected by
immunofluorescence is not cross-reactive with GAD65 [30]. Thus,
whilst the autoantibodies to GAD65 in SPS do recognise the
epitopes that have been defined for sera in T1D, there also
appears to be SPS-specific reactivity to other epitopes as well. In
several studies using SPS sera a major linear epitope has been
identified in the extreme N-terminus of the regulatory sequence in
the N-terminal domain of GAD65 that is not detectable in T1D
[27,28,30,31,32,33,34]. The results in this present study are based
on the experiments conducted on GAD N-terminally truncated by
83-aminoacids, the region of greatest amino acid diversity between
the two isoforms [1]. Although the truncated GAD isoforms retain
enzyme activity [13] and retain antibody reactivity not only with
the sera from TID patients [23,24], but also with SPS sera
[unpublished data], a major linear epitope in SPS has been
described within the first 22 amino acids of the N-terminus of
GAD65 [27,35], a region lacking in the GAD65 used in this study.
Our recent study of the physicochemical properties of GAD65
and GAD67 showed that the C-terminal domain of GAD65 that
contains the major GAD65 epitopes has much greater flexibility
and electrostatic charge than the corresponding region of GAD67,
which may explain its greater antigenicity [15]. The same study
allowed characterisation and localisation of particular residues
within the PLP domains, representing a minor region of flexibility
and charge that could represent an epitope region in the PLP-
domain that was present in both GAD65 and GAD67. This could
be the location of a minor cross-reactive epitope that could be
induced by epitope spreading, noting that high affinity antibodies
to GAD65 such as those in the present study, have been associated
with reactivity with multiple epitopes [25]. Although we have
previously identified several physiochemical features of GAD65
such as electrostatic charge, solvation energy and flexibility, that
distinguish it from GAD67 as an antigen [15], it is important to
recognise that none of these characteristics in isolation are
expected to dictate antigenicity. Indeed, the molecular surface of
GAD67 shows, although to a much lesser extent than GAD65,
some of these characteristics [15], and this may explain the cross
reactivity between GAD65 and GAD67.
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